Session » (0711–0730) Vasculitis – ANCA-Associated Poster I

Date: Sunday, October 26, 2025

Time: 10:30AM-12:30PM

Meeting: ACR Convergence 2025

10:30AM-12:30PM: Abstract Number: 0719

A Combined Transcriptomics and Proteomics Approach to Identify Immune Signatures in ANCA-Associated Glomerulonephritis

10:30AM-12:30PM: Abstract Number: 0711

Analytical Performance of a Novel, Fully Automated Multiplexed Microarray Immunoassay Prototype for the Simultaneous Detection of Autoantibodies to GBM, PR3, and MPO: A Multicenter Evaluation

10:30AM-12:30PM: Abstract Number: 0729

ANCA-associated vasculitis – does the type matter?

10:30AM-12:30PM: Abstract Number: 0717

Circulating Bacterial sRNAs are Altered in Patients with Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis

10:30AM-12:30PM: Abstract Number: 0720

Current State of Racial, Ethnic, Sex, and Geographical Diversity in ANCA-associated vasculitis and Giant Cell Arteritis Trials

10:30AM-12:30PM: Abstract Number: 0713

Differentiating Primary Anti-Neutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis from Secondary Forms

10:30AM-12:30PM: Abstract Number: 0712

Effects of Bacterial Secretome on Nasal Epithelial Cell Gene Expression in ANCA-Associated Vasculitis

10:30AM-12:30PM: Abstract Number: 0722

Estimating two-year risk of relapse in individuals with ANCA-associated vasculitis in a randomized controlled trial of plasma exchange and glucocorticoids

10:30AM-12:30PM: Abstract Number: 0714

Factors Associated With Depression And Anxiety In ANCA-Associated Vasculitis Patients: Data From The Almenara Vasculitis Cohort

10:30AM-12:30PM: Abstract Number: 0727

Higher rates of severe sensorineural hearing loss in granulomatosis with polyangiitis (GPA) compared to other antineutrophil cytoplasmic antibody (ANCA) associated vasculitis

10:30AM-12:30PM: Abstract Number: 0728

Incidence and Clinical Characteristics of ANCA-Associated Vasculitis: A Nationwide Study in Spain

10:30AM-12:30PM: Abstract Number: 0718

Incidence of Venous Thromboembolism in Patients with ANCA-Associated Vasculitides – a Nationwide Registry-Based Study from Sweden

10:30AM-12:30PM: Abstract Number: 0730

Levels of Disease Activity and Their Relationship With Health-Related Quality of Life In ANCA-Associated Vasculitis Patients: Data from the Almenara Vasculitis Cohort

10:30AM-12:30PM: Abstract Number: 0723

Neutrophil and Eosinophil Extracellular Traps in Eosinophilic Granulomatosis with Polyangiitis: Phenotype-based Characterization and Response to Mepolizumab

10:30AM-12:30PM: Abstract Number: 0721

Pulmonary Manifestations of Granulomatosis with Polyangiitis and Microscopic Polyangiitis

10:30AM-12:30PM: Abstract Number: 0726

Real-World Avacopan Use in Granulomatosis with Polyangiitis and Microscopic Polyangiitis: Insights from United States Claims Data on Outcomes and Adherence

10:30AM-12:30PM: Abstract Number: 0724

Risk of Drug Induced Liver Injury with Use of Avacopan in ANCA Vasculitis – Results from Real-World Data

10:30AM-12:30PM: Abstract Number: 0725

Sinonasal Symptom Profiles Associated with Disease Activity in an International Cohort of Patients with ANCA-Associated Vasculitis

10:30AM-12:30PM: Abstract Number: 0715

Supervised machine learning algorithm to identify patients with eosinophilic granulomatosis with polyangiitis in France

10:30AM-12:30PM: Abstract Number: 0716

Utility of Follow-Up Cardiac Magnetic Resonance Imaging In Patients With Eosinophilic Granulomatosis With Polyangiitis

« View all sessions from this meeting